Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) announced that interim CEO Alan Bash will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 2:35 p.m. ET. A live webcast and replay will be accessible through the company’s Investor Relations website.

Market Context

LEGN's historical earnings event carried a 5.66% 24-hour reaction, adding context to this scheduled ...

Analysis

LEGN's historical earnings event carried a 5.66% 24-hour reaction, adding context to this scheduled conference appearance. The platform also records Net Selling insider sentiment, a relevant risk factor to monitor.

Key Figures

Conference date: September 15, 2026 Chat time: 2:35 p.m. ET Employees: Over 3,000 employees +1 more

4 metrics

Conference date September 15, 2026 Morgan Stanley Global Healthcare Conference

Chat time 2:35 p.m. ET Scheduled fireside chat

Employees Over 3,000 employees Company description

Replay availability Approximately 48 hours After the webcast

Historical Context

5 past events · Latest: Aug 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Q2 earnings results	Positive	+5.7%	Quarterly revenue growth, profitability, CARVYKTI sales, and cash balance improvements
Jul 28	Earnings call scheduling	Neutral	-1.2%	Company scheduled a conference call to review second-quarter financial results
Jul 27	CEO transition	Negative	-13.3%	CEO resignation and appointment of Alan Bash as interim chief executive
Jun 17	Public offering pricing	Negative	-16.7%	Underwritten offering priced at $29.35 per ADS for 7,700,000 ADSs
Jun 17	Public offering proposal	Negative	-16.7%	Company proposed a $225 million ADS offering from an effective shelf registration

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

LEGN historically aligned with negative reactions to leadership and offering news, while its recent earnings release drew a positive reaction.

Key Terms

car-t cell therapy, relapsed or refractory multiple myeloma

2 terms

car-t cell therapy medical

"forefront of the CAR-T cell therapy revolution"

A therapy that takes a patient’s own immune cells, reprograms them in a lab to recognize and attack specific disease cells, then returns them to the body—think of training and equipping a guard dog to find a particular intruder. Investors care because these treatments can offer dramatic clinical benefits, carry high development and manufacturing costs, and create new, often lucrative markets if they receive regulatory approval and payer support.

relapsed or refractory multiple myeloma medical

"treatment for relapsed or refractory multiple myeloma"

A form of multiple myeloma that either returns after an initial response to treatment (relapsed) or does not respond to standard therapies from the start (refractory). Investors care because these patients represent a clear medical need and a defined market for new drugs or therapies; successful treatments can drive clinical trial value, regulatory approval chances, and potential sales, much like a solution that works where existing approaches fail.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.

The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.

INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
Caroline.Paul@legendbiotech.com

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com

FAQ

When will Legend Biotech (NASDAQ: LEGN) present at the Morgan Stanley Global Healthcare Conference 2026?

Legend Biotech will participate in a fireside chat on September 15, 2026, at 2:35 p.m. ET. According to Legend Biotech, the session will take place at the Morgan Stanley Global Healthcare Conference in New York, offering investors an update from interim CEO Alan Bash.

How can investors access the Legend Biotech (LEGN) webcast from the Morgan Stanley Global Healthcare Conference?

Investors can access the live webcast via the Investor Relations section of Legend Biotech’s website. According to Legend Biotech, the webcast replay will also be available on the same page approximately 48 hours after the live event for on-demand viewing.

Who will represent Legend Biotech (LEGN) at the Morgan Stanley Global Healthcare Conference fireside chat?

Interim Chief Executive Officer Alan Bash will represent Legend Biotech at the fireside chat. According to Legend Biotech, he is scheduled to speak on September 15, 2026, providing insights into the company’s cell therapy business and strategic focus areas.

Will a replay of Legend Biotech’s September 15, 2026 Morgan Stanley conference webcast be available?

Yes, a replay will be available about 48 hours after the live webcast. According to Legend Biotech, investors and other interested parties can access the replay through the Investor Relations section of the company’s website for a limited period.

What does Legend Biotech do and what is CARVYKTI mentioned alongside LEGN?

Legend Biotech is a global cell therapy company and calls itself the largest standalone cell therapy company. According to Legend Biotech, it co-develops and markets CARVYKTI, a one-time CAR-T treatment for relapsed or refractory multiple myeloma, with collaborator Johnson & Johnson.

Where can investors find contact information for Legend Biotech (LEGN) investor and press inquiries?

Legend Biotech lists separate contacts for investor and press inquiries in its announcement. According to Legend Biotech, investors can reach Caroline Paul by phone or email, while media inquiries should be directed to Kim Fox at the provided phone number and email address.